Analysis focus: RARE
Ultragenyx (NASDAQ:RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; and another approval of borosumab (Crysvita) in April - which also happened. We also liked its cash position, both then and now, and its sale of a Rare Disease Priority Review voucher for $130mn. We didn't like its two trial failures from before, and its overpaid purchase of another drug company - but those were already factored into the low price, and the new catalysts, we assumed, would take the stock higher. This too, happened.
The latest news for RARE Is that its Crysvita showed that it could beat conventional therapy in pediatric patients with X-linked hypophosphatemia (XLH), an inherited form of rickets (vitamin D deficiency). These conventional therapies for this rare disease, with about 12,000 patients in the US, are oral phosphate and active vitamin D, which have been used traditionally to improve pediatric rickets. Borosumab demonstrated superiority to these therapies, as we would expect since its approval. The molecule is a "fully human recombinant monoclonla IgG1 antibody that binds to (inhibits) the phosphaturic hormone fibroblast growth factor 23 (FGF23), a hormone that reduces blood levels of phosphorus and active vitamin D by regulating phosphate excretion and active vitamin D production by the kidney."
Top Low Price Stocks To Watch Right Now: Rite Aid Corporation(RAD)
Advisors' Opinion:- [By Paul Ausick]
Rite Aid Corp. (NYSE: RAD) traded down about 0.9% Friday to match a 52-week low of $1.14 after closing at $11.5 on Thursday. The stock’s 52-week high is $2.55. Volume was about 25% lower than the daily average of around 14.4 million. The company had no specific news and shares were trading flat shortly before the closing bell.
- [By Paul Ausick]
Rite Aid
The reported number of Rite Aid Corp. (NYSE: RAD) shares sold short grew from more than 147.44 million to over 155.35 million as of the most recent settlement date, a rise of about 5.4% since May 15. The latest figure was 14.7% of the company’s total float. The number of days to cover fell from 23 to 19. Shares closed Monday at $1.74, within a 52-week range of $1.38 to $4.21. - [By Paul Ausick]
Rite Aid Corp. (NYSE: RAD) dropped about 5.5% Monday to set a new 52-week low of $1.21. Shares closed at $1.28 on Friday and the stock’s 52-week high is $2.55. Volume was about 10% below the daily average of around 14.1 million. The company had no specific news.
- [By Chris Lange]
When Rite Aid Corp. (NYSE: RAD) released its fiscal first-quarter financial results after the markets closed on Wednesday, the company said that it had a net loss of $0.01 per share and $5.39 billion in revenue. Consensus estimates had called for a net loss of $0.01 per share on revenue of $5.32 billion. The same period of last year reportedly had a per-share net loss of $0.01 and $5.44 billion in revenue.
- [By Paul Ausick]
Rite Aid Corp. (NYSE: RAD) dropped about 0.9% Wednesday to set a new 52-week low of $1.14. Shares closed at $1.15 on Tuesday and the stock’s 52-week high is $2.55. Volume was about 20% below the daily average of around 14.2 million. The company had no specific news and may be on track to close flat or a bit better.
Top Low Price Stocks To Watch Right Now: Sony Corp Ord(SNE)
Advisors' Opinion:- [By Ethan Ryder]
Sony Corp (NYSE:SNE) was the target of unusually large options trading on Wednesday. Stock investors bought 7,772 call options on the company. This represents an increase of approximately 1,729% compared to the typical volume of 425 call options.
- [By Leo Sun]
Prior to the launch of Sony's (NYSE:SNE) PS4 and Microsoft's (NASDAQ:MSFT) Xbox One in 2013, various reports suggested that both companies could add new DRM (digital rights management) features which would lock a single copy of a game to a single console or user. But Sony and Microsoft eventually abandoned those plans, probably to avoid an ugly PR backlash that would have throttled their console sales.
- [By Motley Fool Staff]
In this segment of the MarketFoolery podcast, host Chris Hill and Motley Fool Asset Management's Bill Barker consider this somewhat shocking box office news: The Columbia Pictures (SNE) release Venom -- which pulled an ugly 30% fresh rating on review aggregator Rotten Tomatoes -- didn't merely win the weekend. In fact, it almost doubled the take of the No. 2 film -- critical darling A Star Is Born -- and raked in $80 million, topping all previous October debuts. The Fools consider what this means for the various studios involved and the movie business broadly.
- [By Leo Sun]
As a result, only a niche group of gamers use the Rift and Vive for gaming. Sony's (NYSE:SNE) PlayStation VR for the PS4 faces the same problem. It sold 2 million PSVRs by the end of 2017, but that represents a sliver of the 78 million PS4s it sold worldwide.
Top Low Price Stocks To Watch Right Now: Infinera Corporation(INFN)
Advisors' Opinion:- [By Logan Wallace]
BidaskClub upgraded shares of Infinera (NASDAQ:INFN) from a hold rating to a buy rating in a report issued on Thursday.
A number of other analysts have also weighed in on INFN. Morgan Stanley reaffirmed an equal weight rating and set a $9.50 target price (up previously from $8.00) on shares of Infinera in a report on Friday, March 9th. Citigroup reaffirmed a hold rating and set a $12.00 target price (up previously from $8.50) on shares of Infinera in a report on Friday, March 9th. ValuEngine raised shares of Infinera from a sell rating to a hold rating in a report on Tuesday, March 13th. Northland Securities lowered shares of Infinera from an outperform rating to a market perform rating in a report on Monday, March 19th. Finally, Drexel Hamilton reaffirmed a buy rating and set a $13.00 target price on shares of Infinera in a report on Wednesday, March 21st. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $11.35.
- [By Brian Feroldi]
Infinera (NASDAQ:INFN) reported its first-quarter results on Wednesday, May 9. Management at the optical equipment provider told investors last quarter that revenue and margins were starting to rebound nicely from their 2017 lows. But did the company keep its momentum up in the first-quarter? Let's dig into the numbers to find out.
- [By Dan Caplinger]
The stock market performed badly on Tuesday, with major benchmarks finishing down anywhere from 0.5% to 1.6%. Adding to the list of concerns among market participants, signs of economic challenges in Italy brought back memories of past troubles in Europe that extended the length of time that the continent suffered from disruptions following the U.S. financial crisis in the late 2000s. Investors also had to deal with plunging oil prices that led to a flood of buying in the bond market, sending interest rates plunging lower. Bad news also affected several individual companies. JPMorgan Chase (NYSE:JPM), Infinera (NASDAQ:INFN), and CVR Energy (NYSE:CVI) were among the worst performers on the day. Here's why they did so poorly.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Infinera (INFN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Brian Feroldi]
Shares of optical equipment provider Infinera (NASDAQ:INFN) plunged as much as 18% in early-morning trading on Monday. Shares were down about 14% as of 10:20 a.m. EDT. An analyst downgrade appears to be the primary reason for the big downward move.
- [By Nicholas Rossolillo]
After underperforming the broader stock market in 2017, shares of Infinera (NASDAQ:INFN) have rebounded as of late on improving fundamentals. Management was upbeat about its outlook for business, but before piling in, there are some risks investors should be aware of.
Top Low Price Stocks To Watch Right Now: Hostess Brands, Inc. (TWNK)
Advisors' Opinion:- [By Stephan Byrd]
Shares of Hostess Brands Inc (NASDAQ:TWNK) have received a consensus recommendation of “Hold” from the thirteen research firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $15.00.
- [By Money Morning News Team]
Based in Kansas City, Mo., Hostess Brands Inc. (Nasdaq: TWNK) was founded in 1919 and is best known for global brand names that include Twinkies, Ho Hos, Ding Dongs, Dolly Madison, Zingers, Suzy Q, and Donettes.
- [By Logan Wallace]
Get a free copy of the Zacks research report on Hostess Brands (TWNK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Trey Thoelcke]
For a little more high-profile option, there is Hostess Brands Inc. (NASDAQ: TWNK), which has a market cap over $1 billion dollars. It is, of course, the maker of Twinkies and so much more.
- [By Ethan Ryder]
Wells Fargo & Company MN boosted its position in shares of Hostess Brands Inc (NASDAQ:TWNK) by 28.8% in the second quarter, HoldingsChannel.com reports. The firm owned 1,669,338 shares of the company’s stock after purchasing an additional 373,487 shares during the period. Wells Fargo & Company MN’s holdings in Hostess Brands were worth $22,704,000 at the end of the most recent quarter.
No comments:
Post a Comment